Overview

Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat

Status:
Not yet recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
A single dose study to assess the pharmacokinetics (PK) of oxycodone, when PF614 is solution is administered alone and with nafamostat as an immediate-release (IR) solution and/or extended-release (ER) capsule prototypes.
Phase:
Phase 1
Details
Lead Sponsor:
Ensysce Biosciences
Collaborator:
Quotient Sciences
Treatments:
Nafamostat
Naltrexone